Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605603 | 0.85 | HSD11B1 (0.33) | HDAC6HDAC4HDAC3HDAC1PTGS2 | |
| SCHEMBL1386708 | 0.82 | KMT2A (0.39) | CA2HSD11B1 | |
| SCHEMBL1606320 | 0.80 | NPSR1 (0.35) | PTGS2HSD11B1 | |
| SCHEMBL5015320 | 0.78 | HSD11B1 (0.42) | CA2HSD11B1 | |
| SCHEMBL14440420 | 0.77 | CA2 (0.34) | CA2HSD11B1 | |
| SCHEMBL1605585 | 0.77 | HSD11B1 (0.37) | CA2HSD11B1 | |
| SCHEMBL14344693 | 0.77 | MEN1 (0.33) | HSD11B1 | |
| SCHEMBL10249079 | 0.77 | MEN1 (0.33) | HSD11B1 | |
| SCHEMBL5023746 | 0.77 | MEN1 (0.33) | HSD11B1 | |
| SCHEMBL14531582 | 0.77 | MEN1 (0.33) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HDAC6 987/4885HDAC4 852/4885HDAC3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.